Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome
- The approval is based on the ICONIC study as well as 5yrs. of data from supportive studies that evaluate Livmarli in 86 patients with ALGS
- The results from the ICONIC study demonstrated a significant reduction in pruritus that was maintained through 4yrs.
- Livmarli is the first FDA-approved therapy for patients aged ≥1yrs. & the company has received a rare pediatric disease priority review voucher. The therapy will now be accessible to patients with a prescription through MAP that provides insurance coverage- and access support along with financial support options for patients with Livmarl
| Ref: Mirum | Image: Businesswire
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].